Eplerenone administration has beneficial effect on hepatic paraoxonase 1 activity in diabetic mice

Atherosclerosis

Volumn 208, Issue 1, 2010, Pages 26-27

  Noll, Christophe ^a   Messaoudi, Smail ^a   Milliez, Paul ^a   Samuel, Jane Lise ^a   Delcayre, Claude ^a   Janel, Nathalie ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; EPLERENONE; GLUCOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ATHEROSCLEROSIS; CONTROLLED STUDY; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; LETTER; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; STREPTOZOCIN DIABETES;

ANIMALS; ARYLDIALKYLPHOSPHATASE; DIABETES MELLITUS, EXPERIMENTAL; MICE; SPIRONOLACTONE;

EID: 73449134431     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.06.038     Document Type: Letter

References (24)

1. Durrington P.N., Mackness B., and Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 473-480
2. Letellier C., Durou M.R., Jouanolle A.M., Le Gall J.Y., Poirier J.Y., and Ruelland A. Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications. Diabetes Metab 28 (2002) 297-304
3. Rozenberg O., Shiner M., Aviram M., and Hayek T. Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties. Free Radic Biol Med 44 (2008) 1951-1959
4. Yi X., and Maeda N. Alpha-lipoic acid prevents the increase in atherosclerosis induced by diabetes in apolipoprotein E-deficient mice fed high-fat/low-cholesterol diet. Diabetes 55 (2006) 2238-2244
5. Keidar S., Hayek T., Kaplan M., et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 41 (2003) 955-963
6. Messaoudi S., Milliez P., Samuel J.L., and Delcayre C. Cardiac aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density. FASEB J 23 (2009) 2176-2185
7. Robert K., Chassé J.F., Santiard-Baron D., et al. Altered gene expression in liver from a murine model of hyperhomocysteinemia. J Biol Chem 278 (2003) 31504-31511
8. Hedrick C.C., Thorpe S.R., Fu M.X., et al. Glycation impairs high-density lipoprotein function. Diabetologia 43 (2000) 312-320
9. Jafarnejad A., Bathaie S.Z., Nakhjavani M., and Hassan M.Z. Effect of spermine on lipid profile and HDL functionality in the streptozotocin-induced diabetic rat model. Life Sci 82 (2008) 301-307
10. Suzuki J., Iwai M., Mogi M., et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 26 (2006) 917-921
11. Brilla C.G., Matsubara L.S., and Weber K.T. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 25 (1993) 563-575
12. Fraccarollo D., Galuppo P., Schraut S., et al. Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension 51 (2008) 905-914
13. Susic D., Varagic J., Ahn J., Matavelli L., and Frohlich E.D. Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR. Am J Physiol Heart Circ Physiol 292 (2007) H175-H179
14. Funder J.W., and Eplerenone. A new mineralocorticoid antagonist: in vitro and in vivo studies. Curr Opin Endocrinol Diabet Obesity 7 (2000) 138-142
15. Rocha R., Stier Jr. C.T., Kifor I., et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141 (2000) 3818-3871
16. Martinez D.V., Rocha R., Matsumura M., et al. Hypertension. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 39 (2002) 614-618
17. Rocha R., Martin-Berger C.L., Yang P., Scherrer R., Delyani J., and McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143 (2002) 4828-4836
18. Weinberger M.H., Roniker B., Krause S.L., and Weiss R.J. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15 (2002) 709-716
19. Blasi E.R., Rocha R., Rudolph A.E., Blomme E.A., Polly M.L., and McMahon E.G. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63 (2003) 1791-1800
20. Qin W., Rudolph A.E., Bond B.R., et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 93 July (1) (2003) 69-76
21. Baxter J.D., Funder J.W., Apriletti J.W., and Webb P. Towards selectively modulating mineralocorticoid receptor function: lessons from other systems. Mol Cell Endocrinol 217 (2004) 151-165
22. Nguyen S.D., and Sok D.E. Oxidative inactivation of paraoxonase1, an antioxidant protein and its effect on antioxidant action. Free Radic Res 37 (2003) 1319-1330
23. Sanz-Rosa D., Oubiña M.P., Cediel E., et al. Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. Antioxid Redox Signal 7 (2005) 1294-1301
24. Guo C., Martinez-Vasquez D., Mendez G.P., et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 147 (2006) 5363-5373